CohBar, Inc. (CWBR): Price and Financial Metrics


CohBar, Inc. (CWBR): $2.36

0.01 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CWBR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CWBR Stock Price Chart Interactive Chart >

Price chart for CWBR

CWBR Price/Volume Stats

Current price $2.36 52-week high $11.01
Prev. close $2.35 52-week low $1.50
Day low $2.23 Volume 18,560
Day high $2.37 Avg. volume 32,163
50-day MA $1.85 Dividend yield N/A
200-day MA $4.13 Market Cap 6.86M

CohBar, Inc. (CWBR) Company Bio


CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat Alzheimer's disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.


CWBR Latest News Stream


Event/Time News Detail
Loading, please wait...

CWBR Latest Social Stream


Loading social stream, please wait...

View Full CWBR Social Stream

Latest CWBR News From Around the Web

Below are the latest news stories about COHBAR INC that investors may wish to consider to help them evaluate CWBR as an investment opportunity.

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, November 8, 2022MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m pleased

Yahoo | November 8, 2022

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

Company to host conference call and webcast at 5:00 p.m. ETMENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Managem

Yahoo | October 26, 2022

Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | October 21, 2022

7 Nasdaq Stocks to Sell Before They Die 

With more pain ahead for equities, these seven Nasdaq stocks should be the first to be expelled from investors' portfolios.

Alex Sirois on InvestorPlace | September 26, 2022

CohBar Announces Reverse Stock Split

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01am ET on September

Yahoo | September 22, 2022

Read More 'CWBR' Stories Here

CWBR Price Returns

1-mo 39.24%
3-mo 7.27%
6-mo -55.12%
1-year -77.96%
3-year -96.56%
5-year -98.81%
YTD 39.24%
2022 -83.85%
2021 -73.89%
2020 -16.25%
2019 -48.55%
2018 -37.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6889 seconds.